FLT3 and acute myeloid leukemia: Among recent reports, in 2021, Wang et al. revealed an oxoindoline-based selective FLT3 inhibitor as a potential candidate drug against FLT3-ITD-positive AML, which is oftentimes correlated to an adverse prognosis [7,68].